BBIOBridgeBio Pharma, Inc.

$14B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+11.4% YoY

Gross Profit

$74M95.6% margin

Operating Income

-$512M-659.6% margin

Net Income

-$481M-619.7% margin

EPS (Diluted)

$-3.35

Cash Flow

Operating Cash Flow

-$419M

Free Cash Flow

-$426M

Stock-Based Comp.

$92M

Balance Sheet

Total Assets

$623M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.3B

Cash & Equivalents

$377M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$70M	+11.4%
Gross Profit	$74M	$67M	+11.4%
Operating Income	-$512M	-$577M	+11.2%
Net Income	-$481M	-$563M	+14.5%

BBIO FY 2022 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena